Only the Brand Has SmartCoatTM Technology

When you are suffering from depression, it can be reassuring to know that your antidepressant is providing you with coverage 24 hours a day. That’s why brand name WELLBUTRIN XL uses patented SmartCoat technology, allowing for a steady release over a 24-hour period.4-6

This means a consistent level of the active ingredient is available in the body over the course of each day.

Ask for the Brand From Your Pharmacy

There are steps you can take to make sure your pharmacist fills your prescription with brand name WELLBUTRIN XL and not a generic.

Step1

Tell your doctor you want brand name WELLBUTRIN XL. Ask your doctor to write DAW1 or “brand medically necessary” on the prescription. DAW1 means “dispense as written.”

Step2

Let your pharmacy know that you and your doctor want the prescription to be filled for brand name WELLBUTRIN XL.

Step3

Check your prescription before leaving the pharmacy. Brand name WELLBUTRIN XL is a creamy white to pale yellow round tablet that has “WELLBUTRIN XL” on it followed by the dose.7

Questions to ask your doctor or pharmacist

For your doctor
  • Who from your office can help me find out if my insurance company will cover brand name WELLBUTRIN XL?
  • Will you write my prescription for WELLBUTRIN XL so that it specifically asks for the brand name product?
For your pharmacist
  • Am I set up in your system to automatically receive generics?
  • Will you ask me before substituting a brand name with a generic medicine?

If you find you have been given a generic, speak to your doctor to confirm he or she authorized this substitution.

Find out about a simple (and fast!) way to get brand name WELLBUTRIN XL filled at the pharmacy and delivered to your home for free!

How to Take WELLBUTRIN XL

WELLBUTRIN XL is a tablet that comes in 2 dosage strengths7

150 mg

300 mg

Graphic representation of WELLBUTRIN XL. Not actual size.

WELLBUTRIN XL Side Effects

References:
  1. Peters JR. From our perspective: the importance of the physical characteristics of generic drugs. U.S. Food & Drug Administration. https://www.fda.gov/drugs/newsevents/ucm471446.htm. Accessed November 12, 2020.
  2. Straka RJ, Keohane DJ, Liu LZ. Potential clinical and economic impact of switching branded medications to generics. Am J Ther. 2017;24(3):e278-e289.
  3. Brown T. Inactive ingredients in medications cause trouble for some. https://www.medscape.com/viewarticle/910411. Accessed November 12, 2020.
  4. Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005;7(3):106-113.
  5. US Patent 6096341.
  6. US Patent 6143327.
  7. WELLBUTRIN XL (bupropion hydrochloride extended-release) Prescribing Information. Bausch Health Companies Inc.
  8. Modell JG, Rosenthal NE, Harriett AE, et al. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol Psychiatry. 2005;58(8):658-667.
  9. Mayo Clinic. Bupropion (oral route). https://www.mayoclinic.org/drugs-supplements/bupropion-oral-route/description/drg-20062478. Accessed November 12, 2020.
  10. InformedHealth.org. Depression: how effective are antidepressants? https://www.ncbi.nlm.nih.gov/books/NBK361016/?report=printable. Accessed November 12, 2020.
  11. Ashton AK, Jamerson BD, Weinstein WL, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp. 2005;66(2):96-106.
  12. Kelly K, Posternak M, Alpert JE. Toward achieving optimal response: understanding and managing antidepressant side effects. Dialogues Clin Neurosci. 2008;10(4):409-418.
  13. Fortney JC, Pyne JM, Edlund MJ, et al. Reasons for antidepressant nonadherence among veterans treated in primary care clinics. J Clin Psychiatry. 2011;72(6):827-834.
  14. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65(7):959-965.
  15. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000;157(4 suppl):1-45.
  16. Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry. 2006;67(5):736-746.